On January 8, 2025, Catalyst Pharmaceuticals told the SEC that it had settled patent litigation over Firdapse with Teva Pharmaceuticals. Teva got a license to sell generic amifampridine starting February 25, 2035 [1]. Seven months later, Catalyst settled the same fight with a second generic company, Lupin, on the same terms and the same date [2]. A third defendant, Hetero, took neither deal. As of Catalyst’s most recent annual report, Hetero is still in litigation, with a trial scheduled for March 23, 2026, a few weeks before the 30-month regulatory stay on its application runs out [3].
Three companies filed the same kind of application against the same patents. Two ended up with a negotiated date a decade away. One is still rolling the dice in court. That split outcome, not a single up-or-down verdict, is what most Paragraph IV drug patent litigation actually looks like once a case is filed. The framing of ANDA litigation as a binary contest, patent holds or patent falls, describes what happens in the minority of cases that reach a judge. It does not describe what happens to the docket as a whole.
This piece uses Federal Trade Commission settlement filings back to fiscal year 2004, a peer-reviewed event-study of Paragraph IV litigation outcomes, and settlement documents filed with the SEC in 2025 to lay out what a negotiated entry date actually looks like, how often it happens, what the six recurring settlement structures are, and where the antitrust line sits. DrugPatentWatch tracks Orange Book patent data and litigation status for exactly this reason: a compound’s listed expiration date and its actual date of generic competition are frequently two different dates, and the gap between them is set in a private settlement, not a courtroom.
The Short Answer
Once a brand company sues a generic challenger under the Hatch-Waxman Act, the dispute is substantially more likely to end in a settlement that fixes a licensed entry date than in a final court ruling on patent validity. FTC data show that pharmaceutical companies filed between 145 and 245 final Paragraph IV patent settlements with the agency every year from fiscal year 2013 through fiscal year 2021 [4][5]. Court opinions deciding a Paragraph IV case on the merits are comparatively rare by contrast; most cases that are not dropped outright are resolved by agreement before a district court reaches a validity or infringement ruling [6].
In fiscal year 2020, drug companies filed 205 final Paragraph IV patent settlements with the FTC and the Department of Justice. Twenty of them combined an explicit payment to the generic challenger with a restriction on when that challenger could sell. Nineteen of those twenty payments were litigation-fee reimbursements of five million dollars or less. [4]
The entry date in a settlement can land years before the underlying patent expires, on the exact expiration date, or, less often, years after it, depending on what the brand and generic company conclude a court would have done. Getting that date right, rather than just watching a patent’s face-value expiration date on the Orange Book, is the actual forecasting problem for anyone tracking generic competition.
What Paragraph IV Litigation Actually Is
The Hatch-Waxman Act of 1984 lets a generic drug maker rely on the brand company’s safety and efficacy data instead of running its own clinical trials, in exchange for certifying what it intends to do about any patents the brand has listed in the FDA’s Orange Book against that drug [7].
The Four Certifications and Why Only One Triggers a Lawsuit
A generic applicant certifies one of four things about each listed patent: that no patent information was filed, that the patent has already expired, that the applicant will wait for the patent to expire, or that the patent is invalid, unenforceable, or will not be infringed by the generic product. The fourth option is the Paragraph IV certification, and it is the only one that invites a lawsuit, because it is a direct assertion that the brand’s patent will not stop the generic from launching [7].
The 45-Day Window and the 30-Month Stay
Once a generic company files a Paragraph IV ANDA, it must notify the patent holder. The brand then has 45 days to sue for infringement. If it sues within that window, FDA approval of the generic application is automatically stayed for up to 30 months, or until a court rules, whichever comes first [7]. That stay is the single biggest reason brands file suit even when they expect to lose eventually: even a doomed lawsuit buys up to two and a half years of continued monopoly pricing, and it opens a formal negotiating window in which a settlement can be reached before that clock runs out [7].
First-Filer Status and the 180-Day Exclusivity Prize
The first generic company to file a substantially complete Paragraph IV application against a given drug is eligible for 180 days of market exclusivity against every other generic applicant once it starts selling. That exclusivity, not just entry itself, is usually the more valuable prize in the negotiation, and it is a large part of why settlement terms get complicated: a brand company negotiating with a first filer is effectively negotiating the entry date for the entire generic market behind it [8].
The Findings That Matter
Settlements outnumber court decisions in most years covered by FTC data. Final Paragraph IV settlements filed with the FTC ranged from 145 to 245 per year between fiscal 2013 and fiscal 2021, while reported district court opinions deciding a Paragraph IV case on validity or infringement in a given year are a small fraction of that count [4][5][6].
Settlements involving both a generic-facing payment and a sales restriction fell from roughly half of all final settlements in fiscal 2006 to about 8 to 17 percent in most years after fiscal 2013, calculated from FTC Exhibit 1 data [4][5].
In fiscal year 2021, every one of the 33 settlements that combined compensation with a sales restriction attributed that compensation solely to litigation-fee reimbursement; none exceeded the fee-reimbursement category the Supreme Court flagged as low-risk in FTC v. Actavis [1][5].
In an event-study sample of 274 first-to-file Paragraph IV cases from 1985 to 2010, 18 percent were unchallenged, 36 percent settled before a court ruling, and 46 percent were litigated to a district court decision [6].
Brand-firm financial stakes in a litigated Paragraph IV decision average an estimated 4.3 billion dollars per case, against an estimated 204.3 million dollars for the generic challenger, a roughly 21-to-1 asymmetry that pushes both sides toward negotiating rather than litigating to a verdict [6].
Acceleration clauses, which let a settling generic move up its entry date if a third party gets there first, appeared in 154 of 205 final settlements in fiscal 2020 and 166 of 199 in fiscal 2021, meaning the “negotiated date” in most settlements is a floor, not necessarily the actual launch date [4][5].
Brand manufacturers won 57 percent of Paragraph IV cases that reached a district court decision between 1988 and 2012, but that win rate jumped from 41 percent before the 2002 Schering-Plough v. FTC ruling to 60.5 percent after it, evidence that weaker-patent cases increasingly settle rather than go to trial [6].
18 Years of FTC Settlement Data, Tallied
The FTC has published an annual accounting of Paragraph IV settlements since fiscal year 2004, under a reporting requirement in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Four of the more recent reports, covering fiscal years 2018 through 2021, were not released until January 2025, after a multi-year publication gap [5]. Pulling the underlying Exhibit 1 data from the fiscal 2020 and fiscal 2021 reports produces the following tally.
Table: Final Paragraph IV Settlements Filed With the FTC, FY2004–FY2021
Fiscal Year
Final Settlements
With Restriction + Compensation
Calculated Share*
Excluding Fees Under $7M
2004
14
0
0%
0
2005
11
3
27%
3
2006
28
14
50%
13
2007
33
14
42%
14
2008
66
16
24%
15
2009
68
19
28%
11
2010
113
31
27%
17
2011
156
28
18%
25
2012
140
40
29%
33
2013
145
29
20%
15
2014
160
21
13%
11
2015
170
14
8%
5
2016
232
30
13%
1
2017
226
20
9%
3
2018
245
38
16%
2
2019
194
24
12%
3
2020
205
20
10%
1
2021
199
33
17%
0
Source: FTC Bureau of Competition, Exhibit 1, FY2020 and FY2021 MMA reports [4][5]. Calculated share is DrugPatentWatch’s own computation (settlements with restriction and compensation divided by total final settlements per year) and is not a figure published by the FTC.
What the Decline in the Last Column Actually Shows
The last column is the more consequential number. It counts settlements with a generic-facing payment and a sales restriction after excluding the ones where the only payment was a litigation-fee reimbursement under 7 million dollars, the category the Supreme Court in FTC v. Actavis suggested was unlikely to raise antitrust concerns [1]. That count ran as high as 33 in fiscal 2012 and fell to zero in fiscal 2021 [5]. Brands and generics did not stop negotiating payments. They stopped negotiating the kind of payment that survives a rule-of-reason challenge.
The No-AG Commitment Nearly Disappeared
A “no-authorized-generic” commitment, where the brand agrees not to launch its own generic version during the settling company’s 180-day exclusivity window, was one of the clearest forms of in-kind reverse payment identified in early FTC enforcement actions, including the case against AndroGel that became FTC v. Actavis itself [9]. The FTC’s fiscal 2017 report noted that no settlement filed that year contained a no-AG commitment, the first time that had happened since the agency began tracking the term in 2004 [10].
A Six-Type Taxonomy of ANDA Settlement Structures
FTC filings and the underlying settlement agreements sort into a recurring set of structures. This classification is DrugPatentWatch’s own organization of the public record, built around the categories the FTC itself tracks, not an official industry taxonomy.
Type 1: Clean Early Entry, No Compensation
The generic gets a license to enter before patent expiration, and no money or other consideration moves in either direction. This is the largest single category in most FTC reporting years: 170 of the 205 final settlements in fiscal 2020 restricted the generic’s marketing but contained no explicit or possible compensation at all [4].
Case Study: K-Dur and the Line the FTC Drew in 2002
Schering-Plough’s 2001 settlement with Upsher-Smith over the potassium-chloride product K-Dur negotiated an entry date before patent expiry and contained no anticompetitive terms outside the scope of the patent itself, which is why it was distinguished at the time from settlements like Hoechst-Andrx over Cardizem and Abbott-Geneva over Hytrin, which included maximal, patent-expiry entry dates paired with side restrictions [6]. An administrative law judge upheld the Schering-Plough settlement in 2002, a decision the Eleventh Circuit affirmed in 2005 [6][11]. A separate private antitrust suit over the same settlement reached the opposite conclusion in 2012, when the Third Circuit found it anticompetitive and rejected the “scope of the patent” test the Eleventh Circuit had applied [12].
Type 2: At-Expiration Entry
The generic’s license takes effect on the same day the controlling patent expires. No delay, no acceleration, nothing changes hands beyond the license itself.
Case Study: Lipitor and the Compound-Patent Handshake
Pfizer and Ranbaxy settled their worldwide Lipitor patent litigation in June 2008. Ranbaxy received a license to sell generic atorvastatin in the United States effective November 30, 2011, the date the compound patent expired, along with its 180 days of first-filer exclusivity starting on that date [13]. Pfizer stated the settlement did not involve payments that would concern the FTC [14]. In exchange, Ranbaxy received earlier rights to a separate, lower-volume combination product, Caduet [13].
Type 3: Litigation-Fee Reverse Payment
The brand reimburses the generic’s defense costs, typically a few hundred thousand to a few million dollars, alongside a restricted entry date. The Supreme Court in FTC v. Actavis specifically noted that a settlement reflecting avoided litigation costs is the kind of payment that would likely be “justified” and unlikely to trigger antitrust liability [1]. In fiscal 2021, the FTC tallied 33 settlements combining compensation and a restriction; every one of them fell into this fee-reimbursement category, with payments ranging from 100,000 to 7 million dollars and averaging 3.082 million dollars [5].
Type 4: No-AG or Side-Deal Reverse Payment
The brand transfers value beyond litigation costs, commonly a promise not to launch an authorized generic, a favorable supply or distribution agreement, or a license to unrelated products.
Case Study: Provigil and the 300 Million Dollar Business Deals
Cephalon settled patent litigation with four generic challengers to its narcolepsy drug Provigil in late 2005 and early 2006, agreeing to keep them off the market until April 2012 in exchange for more than 300 million dollars structured across roughly a dozen side transactions covering active pharmaceutical ingredient purchases, intellectual property licensing, and co-development rights [15]. The FTC sued Cephalon in 2008, arguing the underlying business deals made no economic sense except as payment not to compete [16]. The case survived to the eve of trial in 2015, when Teva, which had acquired Cephalon in 2012, agreed to disgorge 1.2 billion dollars to compensate purchasers who overpaid because of the delayed entry [15][16].
Type 5: Quantity-Restricted Entry
The generic is licensed to sell only a capped share of the market for a period, then gains unrestricted entry later. The FTC’s January 2025 review of fiscal 2018 through 2021 filings identified 23 agreements across 8 distinct branded products containing this structure, and flagged it as a form of possible compensation that had become increasingly common in that period [17].
Case Study: Exparel’s Two-Tier License
Pacira BioSciences settled its Exparel litigation with three generic challengers, Fresenius Kabi, Jiangsu Hengrui, and eVenus, in April 2025. Fresenius Kabi received a license to sell volume-limited quantities of generic bupivacaine liposome injectable suspension beginning on a confidential date in early 2030, with the volume cap starting in the high single digits as a percentage of total US distribution, and a separate, unrestricted license beginning no earlier than 2039 [18][19].
Type 6: Collapsed Settlement or At-Risk Reversion
The parties negotiate a deal, a regulator or the parties themselves scuttle it, and the case reverts to litigation, sometimes alongside a generic company launching before any court ruling, a maneuver known as an at-risk launch.
Case Study: Plavix, When the Negotiated Date Falls Apart
Bristol-Myers Squibb, Sanofi-Aventis, and Apotex reached a proposed settlement in March 2006 that would have delayed Apotex’s generic clopidogrel until 2011, the year Plavix’s patent expired, in exchange for a minimum 40 million dollar payment to Apotex [20]. The FTC and a group of state attorneys general rejected the deal. Apotex terminated its obligation to pursue it and began shipping generic clopidogrel in August 2006, at roughly 30 percent below the branded price, before any court had ruled on patent validity [20]. Bristol-Myers Squibb disclosed that the at-risk launch reduced Plavix’s US net sales by an estimated 1.2 to 1.4 billion dollars over 2006 [21]. Litigation continued for years afterward; an appeals panel eventually upheld a 442 million dollar judgment against Apotex, capped under a prior agreement at 50 percent of its net Plavix sales [22]. Separately, Bristol-Myers Squibb paid a 2.1 million dollar FTC penalty in 2009 for failing to disclose an oral side commitment tied to the original, rejected settlement [23].
Most-Favored-Entry Clauses: The Acceleration Mechanic Most Coverage Skips
A negotiated entry date in a settlement is frequently not the actual date a generic launches. Most agreements contain an acceleration provision, and a large share of those are structured as a most-favored-entry, or MFE, clause.
How an MFE Clause Works
An MFE clause lets the settling generic move its own entry date up to match whatever earlier date a third-party generic achieves, whether through its own settlement or a court win. The head of generic manufacturer Apotex told Congress in 2009 that this kind of clause had become a standard feature of nearly every settlement by that point [24]. FTC data confirm the mechanic is now close to universal in cases with a restricted entry date: 154 of 157 such settlements in fiscal 2020, and 166 of 167 in fiscal 2021, contained an acceleration provision [4][5].
When Acceleration Triggers Before the Agreed Date
A 2022 NBER working paper on MFE clauses cites the authors’ earlier empirical study finding that among 47 settlements where the first filer’s exclusivity had been forfeited, a third-party generic actually entered before the settling generic’s agreed date in 7 cases, or 14.9 percent, and among 17 settlements with shared exclusivity, that happened in 6 cases, or 35.3 percent [24]. Where a lone first filer retained its exclusivity, the same research found zero instances of a third party entering earlier, because no other generic could legally enter during that 180-day window regardless of any settlement terms [24].
Definitions: MFE Clauses Versus Ordinary Acceleration Clauses
Not every acceleration provision is an MFE clause. Some accelerate a settling generic’s entry based on unrelated triggers, such as the brand’s own sales falling below a threshold or the brand licensing a different generic to an earlier date. An MFE clause specifically ties the settling generic’s date to whatever date a third party achieves, and its economic effect on non-settling challengers is what has drawn the closer antitrust scrutiny [24].
Why Regulators Rarely Flag a Mechanic This Common
The NBER paper’s core argument is that an MFE clause can function as a reverse payment even when no cash changes hands, because it can simultaneously discourage third-party generics from entering early and reward the settling generic with reduced competitive risk, without ever showing up as an explicit dollar figure in an FTC filing [24]. Private antitrust plaintiffs have raised MFE-based claims in litigation over Actos, Loestrin, and Xyrem, with mixed early results: dismissed initially in the Actos matter, vacated and remanded on appeal in Loestrin, and allowed to proceed in the Xyrem multidistrict litigation as of an August 2021 ruling [24].
Why Both Sides Usually Prefer a Number on a Calendar to a Coin Flip
The economic logic behind settling is asymmetric, and the asymmetry itself explains why negotiated dates dominate the volume of resolved cases.
The 4.3 Billion Dollar Versus 204 Million Dollar Stakes Gap
An event-study analysis of Paragraph IV decisions between 1988 and 2012 estimated average financial stakes of 4.3 billion dollars for brand firms and 204.3 million dollars for generic firms in a litigated decision, a roughly 21-to-1 ratio [6]. That gap means a brand company facing even modest odds of losing has far more to protect through a negotiated outcome than a generic company has to gain by forcing a trial, which pushes settlement terms toward outcomes that split a large bargaining surplus, estimated at roughly 1.7 billion dollars per case on average in the same study, rather than testing the patent in court [6].
How the Bargaining Surplus Gets Estimated
The 2020 event-study methodology combines two inputs for each litigated case: the change in a publicly traded firm’s stock price around the district court’s decision, and an estimate of how surprising that decision was, based on similar prior cases with comparable sales levels and filing years. Multiplying the market reaction by an adjustment for how expected the outcome was yields an estimated dollar value of what each side had riding on the decision, which the researchers then use to model how much combined value a negotiated settlement could unlock relative to rolling the dice on a verdict [6].
What Changed After Schering-Plough v. FTC
The 2002 administrative ruling upholding the Schering-Plough and Upsher-Smith K-Dur settlement, later affirmed by the Eleventh Circuit in 2005, is treated in the academic literature as the inflection point after which reverse-payment settlements became substantially more common, because it endorsed a permissive “scope of the patent” standard that several other circuits subsequently adopted before the Supreme Court intervened in 2013 [1][6][11]. Brand-firm win rates in litigated decisions rose from 41 percent before that ruling to 60.5 percent after it, consistent with weaker-patent cases increasingly settling out rather than proceeding to a decision [6].
What FTC v. Actavis Actually Changed
The Supreme Court’s 2013 ruling in FTC v. Actavis held that a reverse-payment settlement is not automatically immune from antitrust scrutiny simply because it falls within the scope of the underlying patent, and instructed courts to apply a rule-of-reason analysis whenever a settlement includes a large and otherwise unexplained payment from the brand to the generic [1]. The Court did not ban reverse payments outright, and it specifically distinguished payments that reflect saved litigation costs or a fairly valued business transaction from payments that exist only to buy delay [1].
What Counts as “Large and Unjustified” After Impax
The FTC’s 2019 case against generic manufacturer Impax over its Opana ER settlement, upheld by the Fifth Circuit in 2021, applied the Actavis framework to find that a payment combined with a no-AG commitment and related promises violated antitrust law, reasoning that a no-AG commitment allowing the generic to earn more than it would against brand competition is itself a form of in-kind payment [9][25]. It remains the clearest post-Actavis appellate application of the rule.
When a Case Still Goes to Trial
Settlement is common, not universal, and the same underlying data explain what tips a case toward a verdict instead.
Patent Strength Is the Deciding Variable, Not Sales Volume
The 2020 event-study research modeled two possible drivers of the shift toward settlement after 2002: weaker patents, or higher-sales drugs where both sides simply have more to protect by settling. The data pointed to patent strength as the dominant factor. Cases that still reached a decision after 2002 involved measurably stronger patents on average than pre-2002 decided cases, even though the drugs involved had nearly double the sales, implying the weaker-patent cases were the ones being filtered into settlement rather than trial [6].
Active-Ingredient Patents Are Harder to Settle Around
Active-ingredient patents, which claim the drug’s chemical structure directly, are infringed almost automatically once a generic copies that structure, so a generic’s only realistic defense is invalidity. Formulation and method-of-use patents leave more room for a non-infringement argument, since a generic can sometimes design around the specific formulation or simply decline to seek approval for a patented use [6]. That distinction shows up in the data: brand firms with an active-ingredient patent in a decided case won at an estimated 70 percent rate, against 41 percent for brand firms without one [6].
Definition: What Makes a Patent Active-Ingredient Versus Formulation
Researchers classify a patent as covering the active ingredient if its primary claim reproduces the drug’s chemical structure or refers to the compound directly, a classification confirmed against FDA-derived data with a documented 99.7 percent match rate. Formulation patents instead claim a specific delivery mechanism, dosage form, or combination, and method-of-use patents claim a particular clinical application rather than the molecule itself [6].
The Toprol XL Surprise
Even a case that looks safely headed toward a brand win can go the other way. Ahead of a January 2006 district court ruling on AstraZeneca’s beta-blocker Toprol XL, analysts at Deutsche Bank put AstraZeneca’s odds of winning at 60 percent [6]. The 2020 event-study model, built on outcomes in comparable cases, estimated the odds closer to 70 percent. The district court ruled against AstraZeneca [6]. Surprises at that level of confidence were rare in the broader sample, occurring in roughly 12 percent of comparably high-confidence cases, but they were not zero, which is itself the argument for why some brand companies still choose to litigate a case they are heavily favored to win rather than pay for certainty [6].
What a Settlement-Aware Forecast Looks Like
A patent’s Orange Book expiration date is a ceiling on brand exclusivity, not a forecast of when generic competition starts.
Why the Expiration Date Alone Undersells the Real Timeline
Type 1 and Type 5 settlements above can move real entry years earlier than expiration. Type 4 and Type 6 settlements, and their occasional collapse into at-risk litigation, can move it later or introduce outright uncertainty about the date. A forecast built solely on listed patent expiration dates will be systematically wrong in a meaningful share of cases, in both directions.
Building the Forecast: What to Track Instead
A more reliable forecast tracks, at minimum, whether a Paragraph IV suit has been filed and against how many ANDA holders, whether any of those suits have settled and on what disclosed terms, whether a first filer has retained, shared, or forfeited its 180-day exclusivity, and whether any acceleration or MFE language in a disclosed settlement could move the date earlier than its stated floor.
Checklist: Signals a Settlement Track Is More Likely Than a Trial Track
The asserted patent is a formulation or method-of-use patent rather than an active-ingredient claim.
Multiple ANDA holders have filed against the same patents, raising the brand’s stakes in any single decision.
The brand has settled with other challengers on the same patents in the same litigation window.
Public statements or SEC filings reference “settlement discussions” rather than an approaching trial date.
What This Means for Brand Manufacturers
The FTC data on litigation-fee-only reverse payments, effectively zero large unexplained payments by fiscal 2021, mean the safest structure for a brand seeking a delayed entry date without inviting antitrust exposure is now well defined: a licensed date tied to a defensible view of the patent’s strength, an acceleration clause that tracks market events rather than manufacturing an artificial no-AG commitment, and compensation capped at documented litigation costs [1][5]. The Impax precedent is the clearer warning: bundling an unexplained payment with a no-AG commitment remains the combination most likely to draw an enforcement action even a decade after Actavis [9][25].
Methodology
The FTC settlement counts and the calculated year-over-year percentage of settlements combining compensation with a sales restriction are drawn directly from Exhibit 1 of the FTC Bureau of Competition’s fiscal year 2020 and fiscal year 2021 MMA reports, which the agency republished together with the fiscal 2018 and 2019 reports in January 2025 after a multi-year gap in publication [4][5]. The percentage column is DrugPatentWatch’s own calculation, dividing each year’s settlements with both restriction and compensation by that year’s total final settlements; it is not a figure the FTC itself publishes. The case-level statistics on litigated outcomes, financial stakes, and win rates come from a peer-reviewed 2020 Journal of Law and Economics study covering 274 filtered, first-to-file Paragraph IV ANDA cases filed between 1985 and 2010, restricted to cases where monopoly at the active-ingredient level was the status quo at filing [6]. Settlement examples were verified against SEC filings, FTC case records and press releases, and contemporaneous trade press, and are included only where a specific entry date, dollar figure, or litigation outcome was independently confirmed in at least one primary source. Dates characterized as estimates or in-progress, such as the pending Hetero trial in the Firdapse litigation, are identified as such rather than presented as resolved.
Key Takeaways
Final Paragraph IV settlements filed with the FTC ran between 145 and 245 per year from fiscal 2013 through fiscal 2021, consistently outnumbering the small annual count of cases actually decided by a court [4][5][6].
Settlements combining a generic-facing payment with a sales restriction, excluding minor litigation-fee reimbursements, fell from 33 in fiscal 2012 to zero in fiscal 2021 [5].
Six recurring settlement structures account for most disclosed agreements: clean early entry, at-expiration entry, litigation-fee reverse payment, no-AG or side-deal reverse payment, quantity-restricted entry, and collapsed settlements that revert to litigation [4][5][6][15][18][20].
Acceleration and most-favored-entry clauses appear in roughly 80 percent of settlements with a restricted entry date, meaning the disclosed date is frequently a floor rather than the actual launch date [4][5][24].
Brand-firm stakes in a litigated Paragraph IV decision average an estimated 21 times generic-firm stakes, the core reason both sides gravitate toward a negotiated date rather than a verdict [6].
Patent type predicts litigation outcome more reliably than drug sales volume: brand firms asserting an active-ingredient patent won an estimated 70 percent of decided cases, against 41 percent without one [6].
FAQ
What is a Paragraph IV certification? It is a generic drug applicant’s certification, filed as part of an Abbreviated New Drug Application, that a patent listed against the brand drug is invalid, unenforceable, or will not be infringed by the generic product. It is the only one of the four Hatch-Waxman certification types that gives the brand company a right to sue for infringement [7].
How long does Paragraph IV litigation typically take before resolution? The 30-month regulatory stay that follows a timely-filed lawsuit is the practical outer boundary in most cases, though litigation can extend past that point if a court has not yet ruled, and settlement can end a case well before the stay expires [7].
What is a reverse-payment settlement? It describes a Paragraph IV settlement in which the brand company, the plaintiff in the underlying suit, transfers value to the generic defendant in exchange for a delayed entry date, the reverse of the usual direction value flows in a patent dispute [1][6].
Are reverse-payment settlements illegal? Not automatically. FTC v. Actavis held they are subject to rule-of-reason antitrust review when they involve a large, otherwise unexplained payment, but the Court explicitly noted that payments reflecting saved litigation costs or a fairly valued business transaction are unlikely to be found unlawful [1].
What is a most-favored-entry clause? It is a settlement provision letting the settling generic move its own entry date up to match an earlier date achieved by a different, third-party generic, whether through that third party’s own settlement or a court win [24].
What is 180-day exclusivity and why does it matter in a settlement? It is the 180-day period during which the FDA will not approve any other generic application once the first Paragraph IV filer begins selling. Because a settlement with the first filer effectively sets the entry clock for every other generic behind it, that exclusivity is frequently the more contested term in negotiations than the entry date itself [8].
Can a generic company launch before a settlement or court ruling? Yes, this is called an at-risk launch, and it carries the risk of a damages judgment if the brand ultimately prevails. Apotex’s 2006 at-risk launch of generic Plavix, after a proposed settlement collapsed, led to a 442 million dollar judgment years later [20][22].
What changed after FTC v. Actavis in 2013? Settlements combining a generic-facing payment with a sales restriction, apart from minor litigation-fee reimbursements, declined sharply in FTC filings over the following years, falling to zero in fiscal 2021, while acceleration clauses and quantity-restricted entry structures became more common [1][4][5][17].
How is a licensed entry date different from a patent’s expiration date? A patent’s Orange Book expiration date marks the latest date a brand’s protection could run. A licensed entry date in a settlement is a separately negotiated date that can fall well before that expiration, exactly on it, or, in quantity-restricted structures, involve a second, later date for unrestricted competition [13][18][19].
What happens when regulators reject a proposed ANDA settlement? The case can revert to active litigation, and a generic company may choose to launch at risk before any court ruling, as Apotex did after the FTC and state attorneys general rejected its proposed 2006 Plavix settlement with Bristol-Myers Squibb and Sanofi [20].
References
Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013). Discussed in Albert, B., & Lamb, H. (2025, January 15). Reverse Payments: From Cash to Quantity Restrictions and Other Possibilities. FTC Competition Matters. https://www.ftc.gov/enforcement/competition-matters/2025/01/reverse-payments-cash-quantity-restrictions-other-possibilities
Catalyst Pharmaceuticals, Inc. (2025, August 25). Form 8-K, Exhibit 99.1: Catalyst Pharmaceuticals Announces Settlement of Firdapse Patent Litigation with Lupin Pharmaceuticals. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/d915025dex991.htm
Catalyst Pharmaceuticals, Inc. (2026). Form 10-K for fiscal year 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1369568/000119312526071525/cprx-20251231.htm
Federal Trade Commission, Bureau of Competition. (2022). Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in FY 2020. https://www.ftc.gov/system/files/ftc_gov/pdf/fy-2020-mma-report.pdf
Federal Trade Commission, Bureau of Competition. (2025). Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in FY 2021. https://www.ftc.gov/system/files/ftc_gov/pdf/fy-2021-mma-report.pdf
Jacobo-Rubio, R., Turner, J. L., & Williams, J. W. (2020). The Distribution of Surplus in the US Pharmaceutical Industry: Evidence from Paragraph IV Patent-Litigation Decisions. Journal of Law and Economics, 63(2), 203–238. https://jonwms.web.unc.edu/wp-content/uploads/sites/10989/2021/06/ParIVSettlements_JLE.pdf
21 U.S.C. § 355(j); Food and Drug Administration regulations at 21 C.F.R. § 314.108 and § 314.53, as summarized in Jacobo-Rubio, Turner, & Williams (2020), supra note 6.
Korn, D. E., Lietzan, E., & Shaw, S. W. (2009). A New History and Discussion of 180-Day Exclusivity. Food and Drug Law Journal, 64, 335–390, as cited in Jacobo-Rubio, Turner, & Williams (2020), supra note 6.
Federal Trade Commission. In the Matter of Impax Laboratories, Inc., Docket No. 9373, Opinion of the Commission (2019, March 28). https://www.ftc.gov/system/files/documents/cases/d09373_impax_laboratories_opinion_of_the_commission_-_public_redacted_version_redacted_0.pdf
Federal Trade Commission. (2020, December 3). FTC Staff Issues FY 2017 Report on Branded Drug Firms’ Patent Settlements with Generic Competitors. https://www.ftc.gov/news-events/news/press-releases/2020/12/ftc-staff-issues-fy-2017-report-branded-drug-firms-patent-settlements-generic-competitors
Schering-Plough Corp. v. FTC, 402 F.3d 1056 (11th Cir. 2005), as discussed in Jacobo-Rubio, Turner, & Williams (2020), supra note 6.
In re K-Dur Antitrust Litigation, 686 F.3d 197 (3d Cir. 2012), as discussed in Jacobo-Rubio, Turner, & Williams (2020), supra note 6.
Pfizer Inc. (2008, June 18). Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_ranbaxy_settle_lipitor_patent_litigation_worldwide
Chemical & Engineering News. (2008, June 23). Pfizer and Ranbaxy End Lipitor Dispute. https://cen.acs.org/articles/86/i25/Pfizer-Ranbaxy-End-Lipitor-Dispute.html
Federal Trade Commission. (2015, May 28). FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished. https://www.ftc.gov/news-events/news/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill-gotten-gains-relinquished-refunds-will
Courthouse News Service. (2015, May 28). Teva Settles Cephalon Case with FTC for $1.2B. https://www.courthousenews.com/teva-settles-cephalon-case-with-ftc-for-1-2b/
Albert, B., & Lamb, H. (2025, January 15). Reverse Payments: From Cash to Quantity Restrictions and Other Possibilities. FTC Competition Matters. https://www.ftc.gov/enforcement/competition-matters/2025/01/reverse-payments-cash-quantity-restrictions-other-possibilities
Pacira BioSciences, Inc. (2025, April 7). Form 8-K, Exhibit: Pacira BioSciences Announces Settlement of U.S. Patent Litigation for Exparel. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/pcrx-p4settlementrelease.htm
Pacira BioSciences, Inc. (2025, August). Form 10-Q for the quarter ended June 30, 2025. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1396814/000139681425000102/pcrx-20250630.htm
Patent Baristas. (2006, August 9). Apotex To Launch Generic Plavix At Its Own Risk. https://patentbaristas.com/archives/2006/08/09/apotex-to-launch-generic-plavix-at-its-own-risk/
Bristol-Myers Squibb Co. (2007). Form 10-K for fiscal year 2006. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000014272/000119312507039915/d10k.htm
Fierce Pharma. (2011, October 19). Court upholds $442M Plavix judgment against Apotex. https://www.fiercepharma.com/sales-and-marketing/court-upholds-442m-plavix-judgment-against-apotex
Federal Trade Commission. (2009). Bristol-Myers Squibb to Pay $2.1 Million Penalty for Failure to Disclose Agreement Involving Substantial Payments to Delay Entry of a Generic Version of the Drug Plavix. https://www.ftc.gov/news-events/news/press-releases/2009/03/bristol-myers-squibb-pay-21-million-penalty-failure-disclose-agreement-involving-substantial
Drake, K. M., & McGuire, T. (2022). Most-Favored Entry Clauses in Drug Patent Litigation Settlements as a Potential Reverse Payment (NBER Working Paper No. 29801). National Bureau of Economic Research. https://www.nber.org/system/files/working_papers/w29801/w29801.pdf
Federal Trade Commission. (2021, April). U.S. Court of Appeals for the Fifth Circuit Upholds FTC’s Opinion Against Generic Pharmaceutical Company Impax. https://www.ftc.gov/news-events/news/press-releases/2021/04/us-court-appeals-fifth-circuit-upholds-ftcs-opinion-against-generic-pharmaceutical-company-impax
